NYXH
NyxoahNYXH
NYXH
About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Employees: 184
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
18% more funds holding
Funds holding: 22 [Q4 2024] → 26 (+4) [Q1 2025]
3.74% less ownership
Funds ownership: 19.72% [Q4 2024] → 15.98% (-3.74%) [Q1 2025]
23% less capital invested
Capital invested by funds: $54.4M [Q4 2024] → $41.8M (-$12.7M) [Q1 2025]
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
86%
upside
Avg. target
$14.50
92%
upside
High target
$15
99%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Stifel Jonathan Block | 86%upside $14 | Buy Maintained | 21 Apr 2025 |
HC Wainwright & Co. Edward White | 99%upside $15 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Based on 3 articles about NYXH published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025
REGULATED INFORMATION June 13, 2025, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 2, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Wednesday, July 2, 2025 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time.
Neutral
GlobeNewsWire
2 weeks ago
Nyxoah to Present at the Jefferies Global Healthcare Conference
Nyxoah to Present at the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 3 – 5, 2025 in New York. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver a corporate presentation on Tuesday, June 4, 2025, at 4:55pm ET.
Neutral
Accesswire
4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / NEW YORK, NY / ACCESSWIRE / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH).
Neutral
Seeking Alpha
1 month ago
Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript
Nyxoah SA (NASDAQ:NYXH ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Pearson Dennis - Investor Relations Olivier Taelman - Chief Executive Officer John Landry - Chief Financial Officer Conference Call Participants Jon Block - Stifel Adam Maeder - Piper Sandler Ross Osborn - Cantor Fitzgerald Suraj Kalia - Oppenheimer & Co. David Rescott - Baird Michael Polark - Wolfe Research Laura Roba - Degroof Petercam Operator Good day and thank you for standing by. Welcome to the Nyxoah First Quarter 2025 Earnings Conference Call.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH).
Negative
Zacks Investment Research
1 month ago
Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.45 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Nyxoah Reports First Quarter Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the first quarter of 2025. Recent Financial and Operating Highlights Received an FDA Approvable Letter indicating the FDA will approve the Company's PMA application for its Genio® system subject to satisfactory completion of a manufacturing facilities, methods and controls review Successfully completed FDA validation requirements, final site inspection in progress at the U.S. contract manufacturing site Revenue for the first quarter of 2025 was €1.1 million, compared to €1.2 million in the first quarter of 2024 Launched Genio® 2.1 patient software upgrade in international commercial markets Cash, cash equivalents and financial assets were €63.0 million at March 31, 2025, compared to €85.6 million at the end of 2024 "We are excited that we are in the final stage of the FDA review process of our Genio® system in the United States," commented Olivier Taelman, Nyxoah's Chief Executive Officer.
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXH
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH).
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH).
Charts implemented using Lightweight Charts™